Resilient Redx Inks Jazz KRAS Pact

The UK biotech has teamed up again with Jazz, banking a $10m upfront fee that will help towards advancing its wholly owned ROCK inhibitor program for fibrosis indications.

Lisa Anson
Lisa Anson • Source: Redx

The UK's Redx Pharma Plc has recovered well from being jilted by Jounce Therapeutics, Inc. at the M&A altar a year ago and has signed another cancer deal with Jazz Pharmaceuticals plc that could be worth up to $870m.

The Alderley Park-headquartered firm has signed an agreement by which Jazz will acquire the firm's KRAS preclinical inhibitor program and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.